Conversation has moved to delivery: the call's center of gravity is how and when real business converts, not whether it
The model's full reasoning — Q3 2018 call → NOThe user wants me to analyze the earnings call transcript and determine if the center of gravity has moved past the question of whether demand exists, and onto the practical mechanics of converting real business into delivered results. Let me analyze the call carefully. Key themes in the call: 1. Amgen's Q3 2018 results - revenue $5.9B, product sales $5.5B 2. New product launches - Aimovig (migraine), Repatha (PCSK9), Prolia (osteoporosis) 3. Biosimilars - KANJINTI and AMGEVITA launched in Europe 4. Pipeline updates - 7 new early stage clinical programs 5. Competitive pressures on legacy products (Neulasta, Enbrel, EPOGEN) 6. Pricing environment and political pressures Let me look at what the analysts are asking about: - Matthew Harrison: biosimilars outlook in Europe - Geoffrey Meacham: strategies to grow OUS business - Ying Huang: Trump administration proposal on Medicare Part B, Aimovig positioning - Terence Flynn: 2019 guidance, pricing dynamics - Chris Raymond: biosimilar eculizumab program - Phil Nadeau: Sensipar litigation - Robyn Karnauskas: Medicare advantage step edits, Neulasta - Michael Yee: BiTE platform, BCMA bispecifics - Geoffrey Porges: growth vs stability, business development - Ronny Gal: biosimilar revenue percentage, pricing environment - Umer Raffat: BCMA trial design, CGRP market - Kennen MacKay: Aimovig free vs paid patients - Cory Kasimov: CGRP access, formulary positioning - Carter Gould: myeloma landscape - Alethia Young: PAC-1 data - Salim Syed: PCSK9, inclisiran - Brian Skorney: Enbrel infringement Now let me assess the two criteria: (1) Is the business being discussed already real? The call discusses: - Aimovig: 100,000+ patients started since launch, 12,000+ prescribers - this is real, actual business - Repatha: 35% growth, leading share in PCSK9 class - real business - Prolia: 15% sales growth - real business - Biosimilars: KANJINTI and AMGEVITA launched in Europe - real business - Legacy products facing competition - real but declining So yes, the business being discussed is largely real and current. The products are launched, patients are being treated, prescriptions are being written.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ERO | Ero Copper Corp. | Q1 2024 | 2024-05-10 | A |
| LINC | Lincoln Educational Services Corporation | Q1 2024 | 2024-05-06 | B+ |
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| DXCM | DexCom, Inc. | Q4 2023 | 2024-02-08 | B+ |
| EMKR | EMCORE Corporation | Q4 2023 | 2023-12-12 | C+ |
| BRBR | BellRing Brands, Inc. | Q4 2023 | 2023-11-21 | B+ |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| GOLD | Barrick Gold Corporation | Q3 2023 | 2023-11-02 | C |
| CMG | Chipotle Mexican Grill, Inc. | Q3 2023 | 2023-10-27 | B+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| PTLO | Portillo's Inc. | Q2 2023 | 2023-08-05 | B |
| AFL | Aflac Incorporated | Q2 2023 | 2023-08-02 | C+ |
| CTO | CTO Realty Growth, Inc. | Q2 2023 | 2023-07-28 | B |
| CDE | Coeur Mining, Inc. | Q1 2023 | 2023-05-11 | C+ |
| SU | Suncor Energy Inc. | Q1 2023 | 2023-05-09 | C+ |
| ULCC | Frontier Group Holdings, Inc. | Q1 2023 | 2023-05-07 | C+ |
| SBRA | Sabra Health Care REIT, Inc. | Q1 2023 | 2023-05-04 | B |
| TACT | TransAct Technologies Incorporated | Q4 2022 | 2023-03-08 | A |
| ADPT | Adaptive Biotechnologies Corporation | Q4 2022 | 2023-02-14 | C+ |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| UAL | United Airlines Holdings, Inc. | Q4 2022 | 2023-01-18 | B |
| PKOH | Park-Ohio Holdings Corp. | Q3 2022 | 2022-11-13 | B |
| CHE | Chemed Corporation | Q3 2022 | 2022-11-01 | B+ |
| TMCI | Treace Medical Concepts, Inc. | Q2 2022 | 2022-08-13 | B+ |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| OGI | OrganiGram Holdings Inc. | Q3 2022 | 2022-07-14 | B+ |
| HLIO | Helios Technologies, Inc. | Q1 2022 | 2022-05-10 | C |
| BFIN | BankFinancial Corporation | Q1 2022 | 2022-05-06 | A |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| FLUX | Flux Power Holdings, Inc. | Q2 2022 | 2022-02-10 | D |
| GTES | Gates Industrial Corporation plc | Q4 2021 | 2022-02-07 | C+ |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| HY | Hyster-Yale Materials Handling, Inc. | Q3 2021 | 2021-11-06 | D |
| KTB | Kontoor Brands, Inc. | Q3 2021 | 2021-11-04 | A |
| LMAT | LeMaitre Vascular, Inc. | Q3 2021 | 2021-10-29 | C+ |
| FFWM | First Foundation Inc. | Q3 2021 | 2021-10-26 | B |
| EGY | VAALCO Energy, Inc. | Q2 2021 | 2021-08-12 | B |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
| EMR | Emerson Electric Co. | Q3 2021 | 2021-08-04 | B+ |
| EHTH | eHealth, Inc. | Q2 2021 | 2021-07-29 | F |
| ALB | Albemarle Corporation | Q3 2018 | 2018-11-08 | B |
| WES | Western Midstream Partners, LP | Q3 2018 | 2018-10-31 | D |
| AU | AngloGold Ashanti's | Q2 2018 | 2018-08-20 | B |
| IRT | Independence Realty Trust, Inc. | Q2 2018 | 2018-08-02 | B |
| KIM | Kimco Realty Corporation | Q2 2018 | 2018-07-26 | B+ |
| JBT | John Bean Technologies Corporation | Q2 2018 | 2018-07-26 | B |
| CP | Canadian Pacific Railway Limited | Q2 2018 | 2018-07-19 | B+ |
| MKC | McCormick & Company, Incorporated | Q2 2018 | 2018-06-28 | C+ |
| FSS | Federal Signal Corporation | Q1 2018 | 2018-05-12 | A |
| EPAM | EPAM Systems, Inc. | Q4 2017 | 2018-02-16 | B |
| AOSL | Alpha and Omega Semiconductor Limited | Q2 2018 | 2018-02-07 | B |
| CPK | Chesapeake Utilities Corporation | Q3 2017 | 2017-11-10 | A |
| RACE | Ferrari N.V. | Q3 2017 | 2017-11-02 | C+ |
| ABM | ABM Industries Incorporated | Q2 2017 | 2017-06-08 | B |
| FIX | Comfort Systems USA, Inc. | Q1 2017 | 2017-04-30 | A |
| GPOR | Gulfport Energy Corporation | Q4 2016 | 2017-02-14 | A |
| ARAY | Accuray Incorporated | Q4 2016 | 2016-08-17 | B |
| LBTYK | Liberty Global's | Q1 2016 | 2016-05-10 | C+ |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
| HXL | Hexcel Corporation | Q4 2015 | 2016-01-22 | B+ |
GOLD · Q3 2023 → YESThe question is: Has the center of gravity of the discussion moved past whether demand exists, onto the practical mechanics of converting already real business into delivered results? YES The transcript shows the center of gravity has shifted to execution mechanics for already-committed operations and growth projects. Management details current production (up QoQ at NGM, Loulo-Gounkoto, Kibali), specific ramp-up challenges and fixes at Pueblo Viejo (gearbox failures, conveyor issues, temporary 70-75% throughput solutions, new assemblages arriving end-2023), tailings permitting, and phased construction at RekoDiq/Lumwana (2025 start, 2028/2026 first production). Analysts press on Q4 production, 2024 profiles (PV >800koz despite delays), recovery rates 70% to design, capital sequencing ($2.5B 2024, peaks 2025-26), and conversion timing (downtimes, relocations, training).
LBTYK · Q1 2016 → YESThe question is: Has the center of gravity of the discussion moved past whether demand exists, onto the practical mechanics of converting already real business into delivered results? YES The call as a whole satisfies both conditions. Management repeatedly frames the business as already real—existing customer bases, price increases already implemented across two-thirds of the footprint, 210,000 new-build homes added in Q1, 330,000 premises released under Project Lightning, 100,000 postpaid mobile subs added organically, BASE integration underway, and the Cable & Wireless transaction closing next week.
DXCM · Q4 2023 → YESThe question is: has the CENTER OF GRAVITY of the discussion visibly moved PAST the question of whether demand for the company's offering exists, and ONTO the practical mechanics of converting busines...